Eszak-Budai Szent Janos Centrumkorhaz
- Address
- lock Available on a paid plan
Eszak-Budai Szent Janos Centrumkorhaz - Multi-Specialty Clinical Research Center
Eszak-Budai Szent Janos Centrumkorhaz is a comprehensive clinical research institution conducting diverse Phase 3 and specialty trials across multiple therapeutic areas. The center demonstrates particular expertise in neurological disorders, psychiatric conditions, and gastroenterological diseases, with a strong focus on innovative therapeutic interventions for both adult and pediatric populations.
- Neurodegenerative and psychiatric disorders including Alzheimer's disease-associated psychosis and major depressive disorder with anhedonia
- Epilepsy and seizure disorders in both pediatric and adult populations, including Dravet syndrome, Lennox-Gastaut syndrome, and focal seizures
- Inflammatory bowel disease research with emphasis on ulcerative colitis treatment and maintenance therapy
- Cardiovascular neurology including acute ischemic stroke and high-risk transient ischemic attack prevention
The research center's portfolio extends to specialized areas including type 1 diabetes mellitus management in adolescents and adults, high-risk prostate cancer treatment protocols, and pediatric infectious disease studies involving gram-negative bacterial infections in neonates and infants. This broad investigational scope reflects the center's commitment to advancing treatment options across the lifespan, from neonatal care through geriatric medicine, with particular emphasis on conditions affecting the central nervous system and chronic inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 13 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Eszak-Budai Szent Janos Centrumkorhaz
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2) | Takeda Development Center Americas Inc. | Phase III | Not Recruiting | Apr 2022 | Nov 2024 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Riliprubart | 2 | Unknown | 2024-10-01 | 2025-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.